Mahlabot Gad 2025: Net Profit Rose, but the 2026 Test Sits in Timorim and Weiler

Getting To Know The Company

Mahlabot Gad is not just another local dairy producer. It is a branded food platform built on two engines that behave very differently: a broad retail business with about 3,000 points of sale, and a professional channel with another roughly 3,000 customers, mainly pizzerias, restaurants, cafes, hotels, and delicatessens. The company produces and markets specialty cheeses, yogurts, sauces, and desserts, with three dairies, a nationwide distribution system built on about 86 distributors and roughly 100 refrigerated trucks, and 374 employees at year-end 2025. On the 2025 sales run rate, that is about NIS 1.9 million of revenue per year-end employee.

The superficial read of 2025 looks very good. Revenue rose 6.6% to NIS 720.8 million, net profit rose 19.2% to NIS 45.9 million, and the company ended the year with no bank debt, NIS 33.0 million of cash, and another NIS 30.4 million of short-term deposits. But that is not the full picture. Operating profit before other expenses and income was almost unchanged at NIS 63.7 million versus NIS 63.8 million in 2024, and operating profit after those items even slipped slightly to NIS 63.0 million. In other words, most of the bottom-line improvement came from the disappearance of financing expense after the IPO, not from a sharp upgrade in the underlying operating economics.

What is working now? Both engines are still growing. The retail segment rose to NIS 425.7 million and the professional segment rose to NIS 295.0 million. In the fourth quarter, after weakness during Operation Rising Lion, the professional segment returned to 6.1% growth and the quarter as a whole rose 8.1% in revenue. What is still not clean? Gross margin fell from 29.1% to 28.0%, the sales growth barely translated into segment profit, and 2026 is opening not as another straightforward improvement year but as a heavy execution phase: a new dairy and logistics center in Timorim, a deeper move into dairy alternatives, and the still-unfinished Weiler acquisition.

That is the core of the story. In 2025 Mahlabot Gad moved from being a strong but relatively leveraged founder-led company into being a public company with a much cleaner balance sheet. But that financial relief does not answer the main question: can the legacy specialty-cheese business generate both growth and better profitability while the company opens a new and expensive front of operational and category expansion at the same time?

The orientation table below summarizes the layers that matter most from the start:

Events And Triggers

The IPO cleaned up the debt, but it did not settle the capital-allocation test

First trigger: the September 2025 IPO. The company received NIS 205.6 million net, repaid about NIS 114 million of its own credit in September 2025 and another NIS 9.5 million at Gadishon, and ended the year with no bank debt at all. That is a dramatic move, because it cut net finance expense from NIS 11.6 million in 2024 to NIS 3.6 million in 2025 and made the balance sheet much more flexible.

But the other side of the coin matters just as much. The same year also included a NIS 31.5 million payment for the exercise of the Beit Yitzhak put option, a NIS 50 million dividend, NIS 13.0 million of intangible-asset purchases, NIS 17.1 million of CAPEX, and NIS 10.3 million of lease-principal payments. So the IPO bought time and removed debt, but it did not leave a company sitting on idle cash. It created an execution window.

Timorim is not a bonus, it is a business-shaping project

Second trigger: the Timorim project. In June 2025 the company signed an agreement for a new dairy and logistics center on 22,000 square meters, under a Triple Net structure, for 24 years and 11 months. The updated project estimate points to a total project cost of NIS 240 million to NIS 260 million, and initial annual rent of NIS 15.6 million to NIS 17 million. At the same time, the company itself expects to invest another NIS 180 million to NIS 200 million in fit-out, equipment, and machinery.

The temptation to see this only as “growth” is a mistake. It is first of all a replacement of the existing manufacturing and logistics base. If it works, the company estimates annual net savings of NIS 13 million to NIS 17 million and, later on, additional sales and EBITDA capacity. If it is delayed, becomes more expensive, or ramps more slowly than planned, the market will get the opposite: a longer obligation layer, heavier capital spending, and a more prolonged transition. As of the report date, the condition precedent for the agreement had still not been met.

Weiler makes the dairy-alternative entry real, but also messier than it first appears

Third trigger: the Weiler deal. The company signed a conditional agreement in July 2025 to buy 51% of Mishk Weiler for about NIS 46 million. In March 2026 the Israeli Competition Authority approval was received, one of the key conditions precedent, but the transaction has still not closed.

Strategically the deal looks sensible: Weiler is active in tofu, meat substitutes, and dairy substitutes. In 2024 it reported NIS 59.9 million of revenue, NIS 11.6 million of EBITDA, and NIS 6.8 million of net profit. The agreement also includes a price-adjustment mechanism if 2025 or 2026 EBITDA falls short of target. That matters because it means that, for both seller and buyer, the economics are not yet fully settled.

But the most interesting detail sits deeper in the notes. About 21% of Weiler’s sales come from dairy-substitute products, and the bulk of that activity is contract manufacturing for Strauss on Alpro products. That activity is expected to wind down over the coming year as Strauss completes its own plant and moves production in-house. So the deal does not only bring entry into the plant-based category. It also brings an immediate need to replace runoff revenue.

Para Para and Remilk are two clues to what the next Gad might look like

Fourth trigger: at the end of October 2025 the company bought the business activity of Para Para, the Jerusalem-area distributor, and began contracting directly with the sub-distributors and employees. By the fourth quarter the company was already saying the move was contributing to better sales-commission economics. It is not a huge transaction, but it does signal an effort to pull part of the distribution layer inward.

Fifth trigger: in June 2025 the company signed the Remilk cooperation package, and in November 2025 launched “The New Milk,” first into the professional market and in early 2026 into retail as well. This is not yet a proven earnings engine, but it does show that the company is not relying only on Weiler for its dairy-alternative entry. It is building several entry paths at once.

Efficiency, Profitability And Competition

The 2025 problem is not growth, it is the quality of that growth

The most important data point in the report is the gap between revenue and operating profit. Sales rose by NIS 44.6 million, but operating profit before other expenses and income fell by NIS 89 thousand. That means the growth created almost no operating leverage.

The company’s own explanation is fully consistent with that read. The average target price of raw milk rose 3.3% in 2025 versus 2024, and by the fourth quarter it was already 5.7% above the prior-year quarter. At the same time, imported-cheese costs were also higher. The result was a drop in gross margin from 29.1% to 28.0%. The top line kept moving, but each liter and each kilo generated less profit.

There is an important market message here. Mahlabot Gad was not hit in 2025 by disappearing demand. Quite the opposite. Both segments grew, the company says its share in the retail market rose to 6.1%, and the fourth quarter even showed improvement in both segments. The problem is that this growth was built inside an environment of expensive inputs, high import costs, and competition that made it hard to pass costs through cleanly.

Two segments are growing, and neither is really leveraging that growth

On the segment split, the retail business rose 6.9% to NIS 425.7 million, but segment profit there barely moved, at NIS 36.2 million versus NIS 36.1 million in 2024. The professional business rose 6.2% to NIS 295.0 million, but segment profit edged down to NIS 27.5 million from NIS 27.7 million.

So even when the company delivers near double-digit retail growth in the fourth quarter and healthy growth in professional, it is still not generating a clean segment-profit uplift. That does not mean the model is weak. It does mean that the current bottleneck is not penetration, service, or distribution. The bottleneck is margin.

In retail, the brand is holding. That is exactly why the margin pressure stands out more

Looking at the retail product basket, specialty and hard cheeses rose 14.1% to NIS 94.1 million, Italian cheeses rose to NIS 142.7 million, and Balkan cheeses rose to NIS 145.1 million. This is the picture of a brand still selling value-added products, not just basic volume.

That matters because it says the profitability pressure is not coming from a collapse in positioning. It is coming from the fact that even with a relatively strong brand, costs rose faster than the company’s ability to generate incremental profit. This becomes even sharper when looking at one customer, a national retail chain, that accounted for NIS 76.1 million of sales, 11.3% of group sales, and 19.1% of retail-segment sales. The company says it does not have a material dependency, but this is still enough concentration to keep in mind where shelf bargaining power sits.

In professional, the recovery is real, but not evenly distributed

The professional segment tells a somewhat different story. On a full-year basis, pizza chains rose 20.7% to NIS 47.9 million, hotel chains rose 19.4% to NIS 21.5 million, and small private customers rose 4.9% to NIS 165.5 million. By contrast, restaurant and cafe chains fell 3.7% to NIS 60.1 million.

That means the recovery is not fully broad-based. It is stronger where there is repeatable volume and standardized demand, such as pizzerias and hotels, and less clean in classic leisure channels. It also fits the company’s own description: the professional market is more sensitive to war, public mood, and eating out, but once conditions stabilize it can rebound quickly.

The value chain is broad, but not actually free of dependency

The company collects more than 50 million liters of milk a year from about 40 producers, but it is also dependent on imported inputs, roughly NIS 100 million a year in foreign currency, and above all on a cold-chain and distribution system that has to work every day. On the supplier side, Dashen is a major contract manufacturer of Bulgarian cheeses, responsible for 11.9% of purchasing in 2025, and the company does not have a short-term substitute for it. This does not break the model, but it does mean the company is not living on “brand strength” alone. It is also living on operating discipline and supply-chain stability.

Cash Flow, Debt And Capital Structure

The right cash frame here is all-in cash flexibility

If you want to understand 2025, you have to pick the right cash framing. Here the relevant frame is all-in cash flexibility, not normalized cash generation. The reason is simple: the story of the year is not only the recurring cash generation of a steady business. It is what was left after everything the company actually did.

On operating cash flow alone, the company generated NIS 56.2 million, against NIS 45.9 million of net profit. That is a good number. But in the same year it also spent NIS 17.1 million on fixed assets, NIS 13.0 million on intangibles, paid NIS 50 million of dividends, NIS 31.5 million for the exercise of the Beit Yitzhak put option, NIS 10.3 million of lease principal, and reduced bank debt by about NIS 77.2 million net. Without the equity injection from the IPO, this year would not have ended with a clean balance sheet.

The implication is clear: Mahlabot Gad’s balance sheet is stronger, but that strength was built from fresh equity, not from a fully matured operating cash engine. That distinction matters because the next stage of the story, Timorim and Weiler, again requires heavy cash use.

Working-capital quality is still reasonable, but growth is already consuming more cash

Receivables rose to NIS 162.5 million from NIS 146.0 million, inventory rose to NIS 69.0 million from NIS 51.7 million, and suppliers and service providers rose to NIS 86.2 million from NIS 71.9 million. Customer days were almost flat at 73 days versus 72, and supplier days stayed at 47. So the company did not buy growth through a material deterioration in commercial terms. But it did need more working capital, mainly because of higher inventory, including milk powder, butter, and imported raw material brought in during December.

That is exactly the kind of point that is easy to miss. Gad’s 2025 growth does not look subsidized by unusual customer credit or a sharp stretch in supplier terms. On the other hand, it is clearly beginning to consume more inventory and more working capital, and that is before the move to a new site and a broader category set.

Bank debt disappeared, but the fixed obligation layer did not

At year-end 2025, short- and long-term bank debt fell to zero. That is a sharp shift from NIS 77.2 million of bank debt a year earlier. The bank covenants also now look comfortably far from pressure: equity stands above NIS 287 million against a NIS 40 million floor, and the debt-coverage ratio is zero against a ceiling of 3.

But zero bank debt does not mean zero obligation layer. The company still has existing lease liabilities of NIS 26.9 million, and more importantly, the Timorim agreement is not yet fully sitting on the current balance sheet, but it already points to a much heavier future commitment layer. This is exactly the kind of case where you have to distinguish between a clean balance sheet today and an obligation path that is already on the way.

What is really left in the cash box after this year

At year-end the company held NIS 33.0 million of cash and another NIS 30.4 million of short-term deposits. Together, NIS 63.4 million. That looks like a comfortable cushion, but the company itself had already earmarked NIS 46 million from the IPO proceeds for the completion of the Weiler deal after the remaining conditions are met, and the next stage in Timorim requires NIS 180 million to NIS 200 million of company investment.

So the cash left is not really “free cash” in the ordinary sense. It is much closer to transition capital. Enough to move from the old leveraged phase into the new investment phase, but not enough to remove the funding question from the table for the next few years.

Outlook

First finding: 2025 net profit looks better than 2025 operating economics. Anyone focusing only on the bottom line will see a jump. Anyone focusing on operating profit and gross margin will see a much more mixed year.

Second finding: 2026 looks like a proof year. Not because of a survival problem, but because the company has moved from the IPO and debt clean-up stage into the point where it now has to prove that the core business can carry the next expansion phase.

Third finding: Timorim is not yet a cost saving. Right now it is a legal, planning, and capital commitment with large future upside if executed well.

Fourth finding: The Weiler deal brings category entry, a plant, and know-how, but also a revenue-replacement task because part of the current activity is not stable over time.

Fifth finding: The external backdrop is easing only partially, and not enough to call 2026 a harvest year. The milk target price fell to NIS 2.43 per liter in the first quarter of 2026, and later to NIS 2.42 in the second quarter, but this is still an industry with competition, imports, and heavy fixed costs.

2026 is a proof year, not a harvest year

The company itself defines the second stage of its strategy, 2025 through 2029, as the phase of IPO, entry into the wellness world, and migration to a new dairy and logistics center. That wording matters. It says management does not think 2026 is about harvesting the gains. It is about getting the moves done.

That is also why it would be wrong to treat lower finance expense as a substitute for operating improvement. Lower financing cost buys quiet. It does not prove that the company already knows how to generate higher EBITDA from the core business. At this stage 2026 will be judged on a very practical list: do margins stabilize, does Weiler close, does Timorim stay on schedule, and does the dairy-alternative expansion avoid getting ahead of the stabilization of the traditional base?

What has to happen over the next 2-4 quarters

The first requirement is that the better milk-price environment has to start flowing back, at least partly, into margins. If raw-milk pricing eases in 2026 and gross margin still does not improve, the market will conclude the problem runs deeper than input costs alone.

The second requirement is that the Weiler deal closes, but not just closes. The company will need to explain how it replaces the dairy-substitute activity at Weiler that relied on Strauss, and how it turns the transaction from a purchase price into an earnings capability.

The third requirement is real progress in Timorim. Not just a long-term story, but milestones. Satisfaction of the condition precedent, receipt of the permit, adherence to the construction framework, and later also better clarity on how much of the investment really falls on the company versus the landlord side.

The fourth requirement is capital discipline. After a year in which new equity went to debt repayment, dividends, a put-option payment, and ongoing investments, 2026 will need to show clearer prioritization.

What the market may miss on first read

On first read the market may see 2025 as a year of higher profit, zero bank debt, revenue growth, and regulatory approval for the Weiler deal. That read is not wrong. It is just incomplete. Underneath it sits a company that has not yet proved the operating improvement needed to justify the next expansion phase.

That is exactly what may shape the market reading over the coming months. If the first 2026 reports show better gross margin, controlled working capital, and visible progress in Weiler and Timorim, the market may revise the 2025 read upward. If not, the IPO may increasingly be read as a move that mainly bought time.

Risks

Execution risk has moved from one day of sales to several years of project delivery

The first risk is Timorim. The company is effectively committing to a path of a new dairy and logistics center, long-duration rent, large capital spending, and a construction process dependent on a condition precedent, building permits, and execution. This is a very different risk from ordinary quarterly sales pressure. It is a multi-year execution risk.

At Weiler there is both integration risk and revenue-replacement risk

The second risk is Weiler. Entering plant-based categories may be exactly the right strategic move. But if a deal built on 2024 EBITDA enters a phase in which a key dairy-alternative customer moves production in-house, the company will have to prove quickly that the value is not resting on runoff activity.

FX, imports, and the milk target price still matter more than they first seem

The company is exposed to imports of raw materials and products of about NIS 100 million a year in foreign currencies, and runs only partial hedging. Any sharp FX move or import disruption can again hit margins. At the same time, the domestic dairy industry remains regulated and dependent on the target-price mechanism, sector reform, and tariffs. These are not theoretical risks. They were already inside the 2025 numbers.

Concentration is not threatening, but it is not trivial either

One retail customer accounts for 11.3% of sales, Dashen accounts for 11.9% of purchasing, Ezra Cohen is still defined as a key person, and the company still operates with a meaningful related-party legacy around it. None of these elements looks like a thesis-breaking risk on its own right now, but together they are a reminder that this is still a founder-DNA company with a few clear points of dependency.

The market itself is not signaling external pressure right now

There is one place where the story is calm. Short-interest data is nearly zero, 0.00% of float at the end of March 2026, against a sector average of 0.11%, and SIR of 0.02. So at least for now the market is not building an aggressive short thesis against the stock. The debate is not short-driven. It is operational.

---

Conclusions

Mahlabot Gad is ending 2025 as a company that is financially better positioned than a year earlier, but not necessarily equally stronger operationally. The core business is still growing, both segments are functioning, the brand is holding, and the IPO erased bank debt. On the other hand, gross margin compressed, operating profit barely improved, and the company is now entering a phase where almost every large move, Timorim, Weiler, dairy alternatives, also adds real execution load. In the short term the market will focus on that gap: how much of the 2025 improvement was truly fundamental to the business, and how much mainly came from balance-sheet clean-up.

Current thesis in one line: Mahlabot Gad bought itself time and flexibility through the IPO, but 2026 will decide whether the operating core can support the expansion into Timorim and Weiler without leaving the company with only a prettier net-profit line built on cleaner financing.

What changed versus the older understanding of the company: 2025 moved the central question from growth and branding to earnings quality and capital allocation. The growth is still there. Now the issue is whether that growth stays high quality once the company opens the next stage.

The strongest counter-thesis: the cautious read may be missing the real improvement. Both segments grew, retail market share increased, the fourth quarter already recovered, and the cleaner balance sheet may let the company turn Timorim and Weiler into a faster-than-expected step up.

What could change the market interpretation in the short to medium term: gross-margin improvement already in the first half of 2026, closing the Weiler deal with a clear replacement plan for the runoff activity, or on the other hand delays at Timorim and continued flat operating profit despite sales growth.

Why this matters: Mahlabot Gad is no longer judged only as a successful specialty-cheese brand. It is now judged as a public food company trying to expand both its operating base and its category footprint, and the question is whether it can do that without damaging earnings quality and financial flexibility.

What must happen over the next 2-4 quarters for the thesis to strengthen: margins need to improve, Weiler needs to move from strategic option to closed transaction with a clear plan, and Timorim needs to move from estimates to real milestones. What would weaken the thesis? Another stretch of reports in which net profit still looks good because of cleaner financing, while operating profit fails to lift.